Segment Reporting

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Segment Reporting

(14)

 Segment Reporting

In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single business segment, which is the development and commercialization of therapeutic and diagnostic products that service women’s reproductive health needs (fertility and permanent birth control).

The determination of a single business segment is consistent with the financial information regularly provided to the Company’s chief operating decision maker (“CODM”). As a single reportable segment entity, the Company’s segment performance measure is net income (loss) attributable to shareholders. The measurement of segment assets is reported on the balance sheet as total assets. The Company’s CODM is its Chief Executive Officer and Chief Financial Officer, who together review and evaluate net income for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

Significant segment expenses, as provided to the CODM are as follows:

		Three Months Ended March 31,
		2026	2025
Sales	$	424,889	341,264
Cost of sales (excluding depreciation expense)		158,606	117,266
Research and development expense		438,800	959,162
Other research and development expense 1		870,601	2,009,310
Total research and development expense		1,309,401	2,968,472
Sales and marketing expense		1,315,755	908,567
General and administrative expense		1,782,390	1,722,713
Depreciation and amortization expense		82,270	84,853
Total operating expenses		4,489,816	5,684,605
Total other income (expense), net		5,069,633	(440,420	)
Income (loss) before income taxes		846,100	(5,901,027	)
Income tax benefit		—	(4,188	)
Net income (loss)	$	846,100	(5,896,839	)

¹ Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.